Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arnab Basu

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline UpdateRohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
European Urology Oncology|July 16, 2024
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder CancerJohn P Sfakianos, Arnab Basu, George Laliotis, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline UpdateRohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
The Oncologist|June 19, 2025
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimensJeffrey Zhong, Albert Jang, Bashar Abuqayas, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer|December 9, 2021
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) studyVadim S Koshkin, Nicholas Henderson, Marihella James, et al.
Clinical Genitourinary Cancer|February 5, 2026
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE DatabaseAlbert Jang, Tanya Jindal, Ali Raza Khaki, et al.
European Urology|September 15, 2025
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE StudyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Pageof 9